US.DGX · Quest Diagnostics

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.4204215818990527,
        "turnoverUsdM": 108.24102672,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.DGX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 196.8272,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 4.8,
      "take_profit_price": 217.182,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.840843163798105,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 56.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 49.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 208.599,
    "ma50": 200.463,
    "close": 206.84,
    "prevClose": 207.66,
    "avgVolume20": 863580,
    "volumeRatio": 0.61,
    "changePercent": -0.39
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.004077669902912584,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.5928794376058596,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.826684703706488,
      "volat_points": 0,
      "day_range_pct": 0.018902982982015138,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 56.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 74,
        "contribution": 3.7
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 8.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 58.67,
        "contribution": 8.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 17.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 58,
        "contribution": 17.4
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 49.9,
    "details": [
      "基本面分析總分: 3.7/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 8.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 17.4/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.7,
      "資金流": 6.8,
      "市場環境": 8.8,
      "情緒分析": 4,
      "技術信號": 17.4,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.4,
          "epsPoints": 0.4,
          "roePoints": 0.4,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 108.24102672,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DGX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.65
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 714.6675042500001,
                "ma50": 719.2912024000001,
                "name": "QQQ",
                "close": 708.95001,
                "points": 0.4
              },
              "spy": {
                "ma20": 744.9830078499999,
                "ma50": 744.87960204,
                "name": "SPY",
                "close": 748.28003,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.4204215818990527,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 1.8,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140869905,
                "url": "https://finnhub.io/api/news?id=7c44cbdf232fd722d46c7c1836b6ff306d3c7cf5dce2f2dc1a99ca8db8c171f0",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes the \"Best Dividend\" screen with a sustainable 1.59% yield, low 35% payout ratio, and strong profitability. A solid choice for reliable dividend income and growth.",
                "category": "company",
                "datetime": 1783763431,
                "headline": "Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability"
              },
              {
                "id": 140791609,
                "url": "https://finnhub.io/api/news?id=1163bcc6bf803bb433b2cba9b963d451d95a47f2b2b2a3bc11367cdfed6d0641",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1782998102,
                "headline": "Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?"
              },
              {
                "id": 140734708,
                "url": "https://finnhub.io/api/news?id=50937ef665125a5be1abc99b47e86bdc8fdd6ca126ac9b39982f3129f5910fda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide use for detecting residual or recurrent cancer. The approval follows published research indicating the test’s high sensitivity for minimal residual disease monitoring. Quest Diagnostics also entered a national partnership with Attunio Health to support an AI powered precision psychiatry platform. The partnership is intended to provide scalable laboratory infrastructure...",
                "category": "company",
                "datetime": 1782472066,
                "headline": "Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry"
              },
              {
                "id": 140725943,
                "url": "https://finnhub.io/api/news?id=1cda39d77b9b3a359e1e145120f4ed6ac13bbd5d0df48bd64b01106b20f0d053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.",
                "category": "company",
                "datetime": 1782397560,
                "headline": "DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH"
              }
            ],
            "raw_source": [
              {
                "id": 140969627,
                "url": "https://finnhub.io/api/news?id=4c5f5d84c5f21b37ba67458887dddbc1ebc9a066d2574ffc3e222d8be1dba7b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "FAST, GD, UNH, TXRH and DGX are five stocks that combine long records of uninterrupted payouts with stable earnings and solid cash flow.",
                "category": "company",
                "datetime": 1784631720,
                "headline": "5 High Dividend Yield Stocks to Buy for a Stable Portfolio in 2H 2026"
              },
              {
                "id": 140940379,
                "url": "https://finnhub.io/api/news?id=313b6b852fad87101bd818b159b0149e5266b64044b5717f092ff2ac4d12ad63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read here for an analysis.",
                "category": "company",
                "datetime": 1784329960,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 19"
              },
              {
                "id": 140898445,
                "url": "https://finnhub.io/api/news?id=8cce6b82d94a14e6f1c6129d038c9d068492f45c6095479b1ffc1aafdad7bbfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.",
                "category": "company",
                "datetime": 1784037480,
                "headline": "Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus"
              },
              {
                "id": 140898225,
                "url": "https://finnhub.io/api/news?id=b650bd0404d07d15723345af5bfd6859bfe7fe9df9d504ab0885e15a63cbfe95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.",
                "category": "company",
                "datetime": 1784036040,
                "headline": "Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?"
              },
              {
                "id": 140886479,
                "url": "https://finnhub.io/api/news?id=8d5d12187252ef0e8147e50d9c59ae99b9b436fe3ec1128d445997fa97f1f15a",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Baird  analyst Eric Coldwell   maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.",
                "category": "company",
                "datetime": 1783929439,
                "headline": "Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236"
              },
              {
                "id": 140869905,
                "url": "https://finnhub.io/api/news?id=7c44cbdf232fd722d46c7c1836b6ff306d3c7cf5dce2f2dc1a99ca8db8c171f0",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes the \"Best Dividend\" screen with a sustainable 1.59% yield, low 35% payout ratio, and strong profitability. A solid choice for reliable dividend income and growth.",
                "category": "company",
                "datetime": 1783763431,
                "headline": "Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability"
              },
              {
                "id": 140861842,
                "url": "https://finnhub.io/api/news?id=dea4a96367e9b1a7e12508fa236e7172cb3413edda8b934757bfbaf6b5228b7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Nearly one in five workers in the general U.S. workforce (19.1%) tested positive for drug use based on an analysis of hair specimens collected in 2025, an increase of nearly 46% compared to 13.1% in 2021, finds the 2026 Quest Diagnostics Drug Testing Index™. For more information, visit www.QuestDiagnostics.com/DTI.",
                "category": "company",
                "datetime": 1783689840,
                "headline": "One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns"
              },
              {
                "id": 140840711,
                "url": "https://finnhub.io/api/news?id=70f8fddaf6c1d9f28cfb731d0d184f3c03704f72b9b47c49b3aad0e44c40e3a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. Flatiron Health is a leading healthtech company dedicated to expanding the possibilities of point-of-care soluti",
                "category": "company",
                "datetime": 1783515120,
                "headline": "Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI"
              },
              {
                "id": 140821261,
                "url": "https://finnhub.io/api/news?id=b7403286549b8549769139c3ef0d824ea7877567456fd904a8591fea24374fc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Zacks highlights PDF Solutions, LifeStance Health and Paychex among stocks and portfolios that outperformed as markets weighed softer jobs data and earnings.",
                "category": "company",
                "datetime": 1783343700,
                "headline": "Beat the Market the Zacks Way: PDF Solutions, LifeStance Health, Paychex in Focus"
              },
              {
                "id": 140795133,
                "url": "https://finnhub.io/api/news?id=52987caaba1d0a4214a3d3520e4a63c4492060fd2ae8de73a16ba58c60747c14",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Explore this week’s dividend updates.",
                "category": "company",
                "datetime": 1783015043,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 5"
              },
              {
                "id": 140791609,
                "url": "https://finnhub.io/api/news?id=1163bcc6bf803bb433b2cba9b963d451d95a47f2b2b2a3bc11367cdfed6d0641",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1782998102,
                "headline": "Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?"
              },
              {
                "id": 140784902,
                "url": "https://finnhub.io/api/news?id=9dfd63db8152d602bfa95049a98803d3a06a30879dfcd935c88a530be20311fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.",
                "category": "company",
                "datetime": 1782917204,
                "headline": "Quest Diagnostics's Q2 2026 Earnings: What to Expect"
              },
              {
                "id": 140773035,
                "url": "https://finnhub.io/api/news?id=1a9df6d3e66681b87e33417a87fd52ba6bc6e255861fda7aeefb02e7c54e5838",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1782826803,
                "headline": "Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 140764106,
                "url": "https://finnhub.io/api/news?id=f4fbe12de44dd4368caac0162ec6b1a256f57d5dae0fc7960291663304ece869",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximately USD 3.28 Billion in 2025 and is expected to reach USD 3.72 Billion in 2026 and is expected to reach around USD 12.47 Billion by 2035, at a CAGR of 14.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laborato",
                "category": "company",
                "datetime": 1782754200,
                "headline": "Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"
              },
              {
                "id": 140762661,
                "url": "https://finnhub.io/api/news?id=436a621c27ef4c5a4c8af1390e6ab512fb77305db81ffffa5d81207c83cb97fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.",
                "category": "company",
                "datetime": 1782739200,
                "headline": "How Abbott's Largest Segment Is Preparing for the Next Growth Phase"
              },
              {
                "id": 140734708,
                "url": "https://finnhub.io/api/news?id=50937ef665125a5be1abc99b47e86bdc8fdd6ca126ac9b39982f3129f5910fda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide use for detecting residual or recurrent cancer. The approval follows published research indicating the test’s high sensitivity for minimal residual disease monitoring. Quest Diagnostics also entered a national partnership with Attunio Health to support an AI powered precision psychiatry platform. The partnership is intended to provide scalable laboratory infrastructure...",
                "category": "company",
                "datetime": 1782472066,
                "headline": "Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry"
              },
              {
                "id": 140727543,
                "url": "https://finnhub.io/api/news?id=182b2260ba9344f85327967d71459609737e7d419a96acbfa7cca68fadeda24b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Just days after publicly launching its AI-powered precision psychiatry platform and gaining early media attention, Attunio Health announced a major expansion of its clinical infrastructure by selecting Quest Diagnostics as its national laboratory backbone and integrating Getlabs for at-home blood collection.",
                "category": "company",
                "datetime": 1782406380,
                "headline": "Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs"
              },
              {
                "id": 140725943,
                "url": "https://finnhub.io/api/news?id=1cda39d77b9b3a359e1e145120f4ed6ac13bbd5d0df48bd64b01106b20f0d053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.",
                "category": "company",
                "datetime": 1782397560,
                "headline": "DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH"
              },
              {
                "id": 140724703,
                "url": "https://finnhub.io/api/news?id=351b3eb19e715a16d21f59dd642061c9d64d6f75ffe01be0818f08d68b71cae8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Axtria Inc., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme \"Industrializing Intelligence: The Agentic Enterprise.\" More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed.",
                "category": "company",
                "datetime": 1782389700,
                "headline": "Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI"
              },
              {
                "id": 140713099,
                "url": "https://finnhub.io/api/news?id=53dc744169136354e0769d3a58cf2b9dffb00df921da0fa90d1ef76305498a44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.",
                "category": "company",
                "datetime": 1782305520,
                "headline": "Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing"
              },
              {
                "id": 140717728,
                "url": "https://finnhub.io/api/news?id=18a5ba95dece6d3530402100f606cc8aa177cbabfe20db44473b936f9d8747c5",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has",
                "category": "company",
                "datetime": 1782291347,
                "headline": "Quest Diagnostics Receives New York's Department of Health's Clinical Laboratory Evaluation Program Approval For Its Haystack Minimal Residual Disease Liquid Biopsy Test To Trace Residual Or Recurring Disease In Solid Tumor Cancers Patients"
              },
              {
                "id": 140701756,
                "url": "https://finnhub.io/api/news?id=2a5cee0556e50131a61755e46c92560b9e7e0316fe605a444b74909a75e5dd85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DGX gains from Advanced Diagnostics, physician and consumer testing growth, plus AI-driven efficiency efforts, even as debt and policy risks linger.",
                "category": "company",
                "datetime": 1782219540,
                "headline": "Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 4,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 22,
            "discarded_article_count": 18
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.4,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日6日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 895980,
              "down_days": 7,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 838880,
              "avg_vol_20": 882655,
              "avg_vol_30": 895980,
              "range_pct_10": 0.08799071746277311,
              "range_pct_20": 0.12715146973506083,
              "range_pct_30": 0.12748984722490803,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9362708989039934,
              "dist_to_20d_high": 0.056386861313868546,
              "down_shrink_days": 6,
              "breakout_level_20d": 219.2,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6901782328403491
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.4204215818990527,
              "turnoverUsdM": 108.24102672,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.DGX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 196.8272,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 4.8,
            "take_profit_price": 217.182,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.840843163798105,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 5.0064,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.42
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -41.77
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0373
    },
    "kdj": {
      "d": 37.43,
      "j": 50.17,
      "k": 41.68,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 47.14
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -4916508,
      "recentSlope": -326290.8,
      "previousSlope": 68990
    },
    "rsi": 41.78,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 212.0315,
      "position": "SAR喺價上",
      "distancePct": 2.51,
      "previousTrend": "下降"
    },
    "ma50": 200.463,
    "macd": {
      "macd": 1.7686208495954077,
      "trend": "中性偏多",
      "signal": 2.492149845619995,
      "histogram": -0.7235289960245872
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 208.3679,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.61,
      "score": 2,
      "avgVolume": 863580,
      "currentVolume": 523308
    },
    "derived": {
      "ma20": 208.599,
      "ma50": 200.463,
      "prevClose": 207.66,
      "avgVolume10": 793101,
      "avgVolume20": 863580,
      "changePercent": -0.39,
      "avgVolumeForScore": 863580
    },
    "ma_cross": {
      "ma20": 208.599,
      "ma50": 200.463,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 207.936,
      "prevMa50": 200.143,
      "spreadPct": 4.06,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 199.6034,
      "upper": 217.5946,
      "position": "中間"
    },
    "rsi_short": 48.61,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.61
    }
  }
}

{
  "close": 206.84,
  "volume": 523308,
  "changePercent": -0.39
}